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ABSTRACT 
INTRODUCTION 
Clinical guidelines recommend antidepressants as the first line of treatment for adults with 
moderate to severe depression. Randomised trials provide the best evidence on the comparative 
effectiveness of antidepressants for depression, but are limited by a short follow-up and a highly 
selected population. We aim to conduct a cohort study on a large database to assess acceptability, 
efficacy, safety and tolerability of antidepressant monotherapy in people with depressive disorder 
in primary care. 
 
METHODS AND ANALYSIS 
This is a protocol for a cohort study using data from the QResearch primary care research 
database, which is the largest general practice research database in the UK. 
We will include patients registered for at least one year from 1st Jan 1998, diagnosed with a new 
episode of depression and on antidepressant and a comparison group not on antidepressant.  
The exposure of interest will be treatment with antidepressant medications.  
Our outcomes will be acceptability (treatment discontinuation due to any cause), efficacy (clinical 
response and remission); safety (adverse events and all-cause mortality); and tolerability 
(dropouts due to any adverse event) measured at 2 months, 6 months and one year. 
For each outcome, we will estimate the absolute risks for all antidepressants, and relative effects 
between antidepressants using Cox’s proportion hazards models. We will calculate hazard ratios 
(HRs) and 99.9% confidence intervals (CIs) for each outcome of interest.   
 
DISCUSSION 
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The main limitation is the observational nature of our study, while the major strengths include the 
large representative population contained in QResearch and the possibly high generalisability.  
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SUMMARY BOX  
 
What is already known about this subject?  
- In England alone 64.7millions of antidepressants are prescribed. 
- In clinical trials, after two months of treatment an average 26.4% of patients discontinue 
antidepressants due to any cause, and an average of 10.4% of patients discontinue antidepressants 
for side-effects that cannot be tolerated. 
- Clinical trials focus on treatments over short periods of time (8-12 weeks) in highly selected 
patients. 
 
How might it impact on clinical practice in the foreseeable future? 
- This study performed in a large primary care registry may complement evidence provided by RCTs 
and the results might have a high generalisability. 
- This study will inform clinicians, patients and policy makers on the real-world acceptability, efficacy, 
safety and tolerability of antidepressant monotherapy in adults with depressive disorder. 
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INTRODUCTION 
Depression is a very common major health problem, 350 million people in the world are affected.[1] 
There are several effective treatments for depression including drug treatment and talking 
therapies,[2] but clinical guidelines often recommend antidepressant medications as the first 
method of treatment for adults with moderate to severe depression.[3,4,5] Antidepressants are 
very commonly used (in England alone, 64.7m prescriptions for antidepressants were dispensed in 
2016). After two months of treatment, an average 26.4% of patients discontinue antidepressants 
due to any cause, while an average of 10.4% of patients discontinue antidepressants for side-effects 
that cannot be tolerated.[6] This might happen because antidepressants are prescribed without a 
clear understanding of which drug is the most appropriate medication for each patient taking into 
account their characteristics, so people often stop the antidepressant early because they are 
prescribed a drug which might work for the “average person” but has not been tailored to them 
individually.[7] Clinical trials provide the best evidence regarding average comparative efficacy of 
drugs, but they are usually not designed to assess adverse events, especially if they are rare or less 
common. In addition, their external validity is limited because they focus on treatments over short 
periods of time (usually 8-12 weeks) in highly selected patients rather than in more complicated, 
real-world cases, such as patients with multiple co-morbidities and concurrent long-term 
medication that are seen in routine practice by general practitioners (GPs). To understand the 
effects of antidepressants in real world conditions, we aim to conduct a cohort study using a large 
and representative sample from primary care in England, to assess acceptability, efficacy, safety and 
tolerability of antidepressants in adults with depression. 
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METHODS 
 
Setting 
We will undertake the study using data from the QResearch primary care research registry 
(www.qresearch.org). This registry is the largest general practice research database in the UK, and 
it contains in total the anonymised electronic healthcare records of over 35 million patients ever 
registered with 7,500 general practices throughout UK.[8] Consent to provide data for QResearch 
was sought from all UK practices using the Egton Medical Information Systems (EMIS) medical 
records system. EMIS is the major supplier of primary care computer systems in the UK and is in use 
in two-thirds of all UK general practices.  
The information recorded on the QResearch database includes patient demographic data (year of 
birth, gender, socio-economic data), characteristics (height, weight, smoking status), symptoms, 
clinical diagnoses, consultations, referrals, prescribed medications and results of investigations. The 
latest version of the QResearch database, which is updated quarterly, will be used for the analysis.   
Detailed analyses have compared QResearch practices with all UK practices and found that practices 
contributing to QResearch are somewhat larger than UK practices overall but are very similar in 
other respects (e.g. age-sex distribution and prevalence of chronic diseases).[8] Within QResearch, 
we will use data coming from English general practices. 
Population 
We will initially identify an open cohort of patients aged 18-100 years at the study entry date drawn 
from patients registered with eligible practices since 1st Jan 1998. Patients will be included if they 
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have been registered with the practice for at least 12 months. Patients will be followed up for 12 
months. 
We will use Read codes to identify patients with a diagnosis of depression, using as a starting point, 
case definitions that have been used in previous studies (see supplementary file 1).[9,10] We will 
exclude: 
- patients with a recorded diagnosis of bipolar disorder or schizophrenia spectrum disorder 
made at any point during their lifetime; 
- patients with a diagnosis of post-partum depression made within 180 days before or up to 
180 days after the first diagnosis of depression; 
- patients prescribed more than one antidepressant at baseline; 
- patients prescribed antipsychotics or mood stabilisers;  
- patients if they had received prescriptions for an antidepressant or they had a diagnosis of 
depression before their entry date in the cohort; 
- patients with a diagnosis of depression made two months before or two months after 
starting an antidepressant. 
Our final cohort for analysis will include exposed groups of patients on each antidepressant 
monotherapy, and an unexposed group of patients not on antidepressants. 
 
Drug Exposure 
The primary exposure of interest is the use of licensed antidepressants, which will be considered 
individually and also grouped according to the four main classes in the British National Formulary 
(BNF) (https://bnf.nice.org.uk). The groups will consist of tricyclics (TCAs) (i.e. amitriptyline, 
amoxapine, butriptyline, clomipramine, desipramine, dosulepin, doxepin, imipramine, iprindole, 
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lofepramine, maprotiline, mianserin, nortriptyline, protriptyline, trimipramine, viloxazine), selective 
serotonin reuptake inhibitors (SSRIs) (i.e. citalopram, escitalopram, fluoxetine, fluvoxamine, 
paroxetine, sertraline), monoamine oxidase inhibitors (MAOIs) (i.e. isocarboxazid,  moclobemide, 
phenelzine, tranylcypromine) and other antidepressants (i.e. agomelatine, duloxetine, mirtazapine, 
nefazodone, reboxetine, tryptophan, trazodone, venlafaxine, vortioxetine).[11] 
Information will be extracted from all prescriptions for antidepressants issued during 12-months 
follow-up.  We will calculate the duration of each prescription in days by dividing the number of 
tablets prescribed by the number of tablets to be taken each day. If the information on tablets per 
day is missing or not sufficiently detailed (expected to be < 5% of total prescriptions) we will 
estimate the duration of the prescription based on the number of tablets prescribed, as in previous 
studies.[10] Patients will be classified as continually exposed to an antidepressant during periods 
where there were no gaps of more than 30 days between the end of one prescription and the start 
of the next (most antidepressants at the beginning of a treatment are prescribed for not more than 
28-30 days). Patients will be also classified as exposed for the first 30 days after the estimated date 
of stopping an antidepressant in order to account for any delays in starting the prescription or 
accumulation of tablets as well as to attribute the outcomes occurring during withdrawal periods to 
the antidepressant, as done in previous studies.[10] The daily dose of each prescription will be 
calculated by multiplying the number of tablets to be taken each day by the dose of each tablet, and 
then converted to a defined daily dose using values assigned by the World Health Organization’s 
Collaborating Centre for Drug Statistics Methodology (www.whocc.no/atc_ddd_index). 
 
Outcomes 
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We will measure the following outcomes up to two months, six months and one year from the initial 
prescription of antidepressants or from the date of the first episode of depression for patients not 
on antidepressants. We will consider extending the follow-up to two years if data are available. 
 
Primary outcomes 
1) Acceptability of treatment will be measured as all cause treatment dropout rate. 
Treatment dropout will be computed if: 
 - A patient has a gap of more than 30 days between the end of a prescription of an antidepressant 
and the start of the next prescription, or 
- a patient switches to another antidepressant, or 
 - a patient is prescribed an additional antidepressant, a mood stabiliser, or an antipsychotic 
(augmentation). 
2) Tolerability of treatment, measured as treatment dropout (measured as described above) after 
any adverse event occurred (i.e. no subsequent prescriptions or implementation of a 
switch/combination/augmentation strategy after the occurring of an adverse event). Treatment 
dropout would have to occur within 30 days of an adverse event to be assumed to be a consequence 
of the adverse event. The list of adverse events is described below. 
 
Secondary outcomes 
3) Safety, measured as: 
• number of patients with at least one adverse event (AE) among the ones specified below. 
We will use the Read codes for adverse events that have been shown in randomised trials as 
the frequent and severe adverse events of antidepressant. These include: nausea, headache, 
dry mouth, insomnia, dizziness, sedation/somnolence, diarrhoea, constipation, sexual 
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dysfunction, fatigue, rhinitis/ nasopharyngitis, hyperhidrosis, respiratory disorder (infection, 
cough), anxiety, decreased appetite, increased appetite, tremor, pain, vomiting, abdominal 
pain/discomfort, dyspepsia, agitation, visual impairment, ejaculation disorder/erectile 
dysfunction, weight increased, weight decreased, arrhythmia/heart rate disorder, abnormal 
dreams, infection, blood pressure increased, blood pressure decreased, extrapyramidal 
disorders, suicidal ideation, suicide behaviour or self-harm, hot flush, dysuria, skin disorder, 
flatulence, urinary disorders, injury, yawning, eye disorders, paraesthesia, nervous system 
symptoms, feeling cold, menstrual disorder, chest pain, disturbance in attention, libido 
increased, psychiatric symptoms, fall, confusional state, salivary hypersecretion, accidental 
overdose, cardiovascular symptoms (e.g. angina), sleep disturbance, oedema, aggression, 
completed suicide, affect lability, fever, euphoric mood, hypersomnia, memory impairment, 
muscular skeletal problems, serotonin syndrome, withdrawal syndrome, fractures, upper 
gastrointestinal bleeding, bleeding at any site, epilepsy/seizures.  
The classification of the above mentioned side effects is performed based on the use of 
preferred terms from MedDRA (https://www.meddra.org/) to categorise each adverse 
event into categories. MedDRA has been developed by the International Council for 
Harmonisation of Technical Requirements for Pharmaceuticals for Human Use to provide a 
single standardised international medical terminology which can be used for regulatory 
communication and evaluation of data pertaining to medicinal products for human use. As 
a result, MedDRA is designed for use in the registration, documentation and safety 
monitoring of medicinal products through all phases of the development cycle (i.e., from 
clinical trials to postmarketing surveillance). The side effects proposed in our protocol are 
similar to those considered in Tomlinson et al., 2019 [12] as we are focusing on clinically 
relevant outcomes which have been evaluated also in RCTs. 
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• All-cause mortality. Patients who have died will be identified using death data recorded on 
the patients’ general practice record as in previous studies.[10,13]  
4) Efficacy, measured at the last observation before 2, 6 and 12 months, as: 
• Clinical remission, measured as scoring less than a prespecified threshold on a standardised 
rating scale,[6] such as the Hamilton Depression Rating Scale (HDRS), the Montgomery and 
Asberg Depression Rating Scale (MADRS), the Beck Depression Inventory (BDI), the Patient 
Health Questionnaire (PHQ-9), the Geriatric Depression Scale (GDS) (e.g. a score < 7 for the 
HDRS would be considered as remission).   
• Clinical response to antidepressant treatment, measured as 50% reduction on a 
standardised rating scale, compared with the most recent value recorded in the 6 months 
before the first antidepressant prescription. 
 
Confounder variables 
Confounders will include baseline variables that we consider to be potential risk factors for the 
outcomes and are also potentially associated with the likelihood of receiving a particular 
antidepressant treatment, based on previous studies of antidepressants.[9] These include: 
• age at study entry, in years; 
• sex;  
• Body Mass Index (BMI); 
• year of diagnosis of depression; 
• type of diagnosis (major depressive disorders, minor depression, other); 
• severity of index diagnosis of depression (categorised as mild, moderate or severe, using the 
Read codes published by Martinez et al.;[14]  
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• deprivation (Townsend deprivation score corresponding to the patients postcode, in 
fifths);[15]  
• smoking status (non-smoker, ex-smoker, light smoker: 1–9 cigarettes/day, moderate 
smoker: 10–19 cigarettes/day, heavy smoker: ≥ 20 cigarettes/day, not recorded);  
• alcohol intake (none, trivial: < 1 unit/day, light: 1–2 units/day, medium: 3–6 units/day, 
heavy: 7–9 units/day, very heavy: > 9 units/day, not recorded);  
• ethnic group (categorised as either white/not recorded or non-white [Indian, Pakistani, 
Bangladeshi, other Asian, black African, black Caribbean, Chinese, other including mixed]);  
• comorbidities at baseline (binary variables for each of coronary heart disease, stroke/ 
transient ischaemic attack, diabetes, hypertension, cancer, epilepsy/seizures, 
hypothyroidism, osteoarthritis, rheumatoid arthritis, suicidal ideation/behaviour or self-
harm, obesity, asthma/chronic obstructive airways disease, osteoporosis, liver disease, renal 
disease, obsessive-compulsive disorder); and  
• use of other drugs at baseline (binary variables for each of anticonvulsants, hypnotics/ 
anxiolytics, antihypertensive drugs, aspirin, statins, anticoagulants, non-steroidal anti-
inflammatory drugs, bisphosphonates, oral contraceptives, hormone replacement therapy.    
 
Handling of missing data 
Excluding subjects with missing values would reduce the sample study size, thus decreasing 
precision and power.[16] We will use multiple imputation by chained equations to impute values 
when actual values are not available. We will first analyse the pattern of distribution of missing 
values in order to assess if the data are suitable for multiple imputation using chained equations. 
For each imputation we will generate ten imputed datasets and we will combine coefficient 
estimates across these using Rubin’s rules.[17] We will include all of the confounding variables in 
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the multiple imputation process, along with the outcome variable as it carries information about 
predictors’ missing values. 
 
Statistical analysis  
We will use Stata MP 16.0 to conduct statistical analysis. We will follow the “REporting of studies 
Conducted using Observational Routinely-collected health Data” (RECORD) Statement.[18]  
Our primary analysis will be time to event, while self-controlled case-series and propensity score 
will be secondary analysis. 
Descriptive statistics  
We will split the population into antidepressant users and non-users. 
In the study cohort of patients with a diagnosis of depression we will summarise baseline 
characteristics with descriptive statistics and will describe patterns of antidepressant use according 
to type of antidepressant prescribed, duration of use and dose. We will describe the severity of 
depression (classified as mild, moderate or severe) in the study cohort, overall and by age and 
gender. We will describe patterns of antidepressant use according to severity of depression.  
Time to event analysis 
We will determine absolute and relative risks according to type of antidepressant prescribed for 
dropouts due to any cause (acceptability), dropouts due to any adverse event (tolerability), 
response and remission (efficacy), number of patients experiencing at least one adverse event and 
all-cause mortality (safety).  
Incidence rates of all the outcomes above described will be calculated in the study cohort of 
people with a new diagnosis of depression. The statistical analysis will comprise a series of survival 
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analyses to assess the relationship between exposure to each antidepressant monotherapy (and 
antidepressants grouped according to the four main classes in the BNF) and acceptability, efficacy, 
safety and tolerability. Dose of antidepressant drugs will be examined in the analyses. The date of 
entry into the survival analyses will be the date of starting an antidepressant for patients on 
antidepressants and the date of the first episode of depression for patients not on 
antidepressants. The right censor date will be the earliest of the following: date of dropout, date 
of switch to another antidepressant, date of a new antidepressant added, date of a mood 
stabiliser added, date of an antipsychotic added, date of the outcome of interest, date of death, 
date of leaving the practice, or the study end date. Death will be a date of censorship for all of the 
adverse events, except for the analysis of all-cause mortality where date of death is the outcome 
date. 
We will explore non-linear relationships between continuous variables and the outcome using 
fractional polynomials.[19] 
Cox’s proportion hazards models accounting for practice clustering will be used for all time-to-
event analyses. The analyses will calculate hazard ratios (HRs) and 99.9% confidence intervals (CIs) 
comparing:  
1. The risk of acceptability, efficacy, safety and tolerability for each antidepressant will be 
directly compared with each other.  
2. The risk of efficacy and safety in patients on any type of antidepressant compared with 
patients with no antidepressant treatment.  
3. Each separate class of antidepressants (SSRIs, TCAs, MAOIs and other antidepressants) will 
be directly compared with each other for acceptability, efficacy, safety and tolerability and 
compared with no treatment for efficacy and safety.  
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4. Analyses will also calculate HRs according to prescribed dose of antidepressant; where 
numbers are sufficient individual antidepressants within each class will be examined.  
5. Analyses of interaction will be carried out to examine the extent to which patient’s 
characteristics (age, gender), use of other medications and comorbidities modify the 
relationship between antidepressant use and outcomes.  
Adjustment will be made for potential confounders as listed above. The assumptions of the Cox 
proportional hazards model will be checked. In case these assumptions are implausible, we will 
instead employ alternative parametric survival models.  
For acceptability (discontinuation due to any cause), according to results from RCTs, a mean of 
26.4% of patients discontinued the treatment for any cause after the first two months of treatment. 
[6] Considering an alpha of 0.01 and a beta of 0.2, to detect a hazard ratio of 2, 1.5 and 1.2, we 
require a sample size of at least 369, 1077, 5324 patients per treatment, respectively. 
Self-controlled case-series analysis  
The self-controlled case-series analysis only uses the patients in the cohort who have the 
outcomes of interest.[20] Cases with each type of adverse event will be identified; these will be 
cases with a diagnosis of the adverse event since 1st January 1998, who had a new diagnosis of 
depression (see above for details). Information on prescriptions for antidepressants in these cases 
will be extracted and the analysis (such as conditional fixed-effects Poisson regression model) will 
compare rates of the outcomes of interest in periods following a first prescription for an 
antidepressant compared with a baseline period free of antidepressant treatment for the same 
patient.[21] We will account for multiple periods of exposure in the analysis, defining a period of 
antidepressant treatment as one without gaps of more than 30 days between the end of a 
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prescription and the start of the next prescription. A prescription after more than 30 days will 
count as a new treatment episode. The 28 days before the first prescription in each treatment 
period will be considered separately, as occurrence of the outcome of interest in this period could 
affect the probability of an antidepressant prescription. All other time periods outside these 
specified risk periods will contribute to the baseline person time, i.e. the unexposed periods. 
Propensity score 
A propensity score for antidepressant use will be calculated using a logistic regression 
model,[22,23] which will initially include all confounders above mentioned. We will be using the 
whole sample for the analysis.  Antidepressant users will be matched to a common comparator 
(e.g. fluoxetine users) and to non-antidepressant users on the logit of the propensity score using a 
caliper width of 0.2 of the standard deviation of the logit of the propensity score. A matching ratio 
of 1:1 will be used.[24] We will assess standardised differences between the two groups with 10% 
or more considered as suggestive of imbalance.[25] We will then perform a multivariable cox 
regression to estimate the effect of antidepressant on outcome occurrence.  
 
DISCUSSION 
This protocol describes a large cohort study which aims to assess the acceptability, efficacy, safety 
and tolerability of antidepressant monotherapy in adults with depressive disorder in primary care. 
This study is part of the “Personalise antidepressant treatment for unipolar depression combining 
individual choices, risks and big data (PETRUSHKA)” project. PETRUSHKA seeks to ultimately develop 
and test a precision medicine approach to the pharmacological treatment of major depressive 
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disorder by synthesizing data coming from randomized controlled trials (RCTs) and data coming 
from observational studies and patient registries.[12]  
This study builds on a solid foundation of research performed on QResearch on the safety of 
antidepressants use in people aged 20–64 years,[10] and in older people[9] and contributes to the 
field by focusing on clinically relevant outcomes which have been evaluated also in RCTs.  
At present, the best evidence in terms of comparative efficacy and acceptability of antidepressants 
comes from the “Group of Researchers Investigating Specific Efficacy of individuaL Drugs for Acute 
depression (GRISELDA)” study, which was a network meta-analysis including only RCTs.[6] Indeed, 
RCTs are the most reliable source of information on relative treatment effects. However, RCTs have 
strictly experimental settings and employ inclusion criteria which might limit their ability to predict 
results in real-world clinical practice.[26] Large observational studies may complement evidence 
provided by RCTs and potentially address some of their limitations. Recently, Efthimiou et al. [27] 
developed statistical methods for combining randomized and non-randomized evidence in a 
network meta-analysis.[27]  
 
Our study aims to investigate the effectiveness of antidepressant monotherapy in a real-world 
setting.[28] The study design is a cohort study and thus observational in nature.[29] Compared to 
the GRISELDA study, the outcomes will include an in-depth evaluation of side effects, with a longer 
follow-up (one year).  Moreover, in our cohort study we will include a representative population of 
people with depression in England, also including people with multiple comorbidities, who would 
normally be excluded in a RCT. This is because people with multiple comorbidities represent the 
added value of a real-world study, whose results aim to be generalised to a wide population.  
The major strengths of our study include the large population contained in QResearch and the 
potentially high generalisability (external validity). Our study suffers from a number of limitations. 
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First, the main limitation is the weaker internal validity of our study when compared to RCTs due to 
potential indication bias and residual confounding. A recent umbrella review showed that most of 
available evidence from observational studies on antidepressants is actually flawed by confounding 
by indication. [30] Although we used a large number of confounders and propensity score matching 
to control confounding, we are aware RCTs are generally considered to be at a lower risk of bias 
compared to observational studies, when aiming to estimate causal effects of interventions.  
Second, some information before date of entry in QResearch database may have not been recorded. 
For example, we will exclude patients if they had received prescriptions for an antidepressant or 
they had a diagnosis of depression before their entry date in the cohort, but this may have not been 
recorded in all cases. 
Third, we will be not adjusting antidepressants dose for concomitant drugs which may increase or 
decrease antidepressants' metabolism (e.g. carbamazepine).  
Fourth, time to event analyses in patients on any type of antidepressant compared with patients 
with no antidepressant treatment may suffer from survival bias as the start of follow-up for exposed 
individuals is the date of antidepressant prescription, while for unexposed individuals it is the date 
of depression diagnosis. However, this will not affect comparisons between antidepressants which 
is the main focus of our study. 
In the future, we aim to predict the effects of different antidepressants given information on 
patient-level characteristics, by using both statistical and machine learning tools (such as artificial 
neural networks and support vector machines). The present study will identify a range of possible 
prognostic factors and effect modifiers which will be used to inform the predictive model. The 
predictive model will then be used in PETRUSHKA to develop a web-based treatment algorithm to 
help clinicians, patients and carers to personalise the choice of antidepressant in primary care.[12] 
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